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AbstrAct:
Laboratory models show that the beta-blocker, propranolol, can inhibit 
norepinephrine-induced breast cancer cell migration. We hypothesised that breast 
cancer patients receiving beta-blockers for hypertension would show reduced 
metastasis and improved clinical outcome. Three patient subgroups were identified 
from the medical records of 466 consecutive female patients (median age 57, range 
28-71) with operable breast cancer and follow-up (>10 years). Two subgroups 
comprised 43 and 49 hypertensive patients treated with beta-blockers or other 
antihypertensives respectively, prior to cancer diagnosis. 374 patients formed a non-
hypertensive control group. Metastasis development, disease free interval, tumour 
recurrence and hazards risk were statistically compared between groups. Kaplan-
Meier plots were used to model survival and DM. Beta-blocker treated patients 
showed  a  significant  reduction  in  metastasis  development  (p=0.026),  tumour 
recurrence (p=0.001), and longer disease free interval (p=0.01). In addition, there 
was a 57% reduced risk of metastasis (Hazards ratio=0.430; 95% CI=0.200-0.926, 
p=0.031), and a 71% reduction in breast cancer mortality after 10 years (Hazards 
ratio=0.291; 95% CI=0.119-0.715, p=0.007). This proof-of-principle study showed 
beta-blocker therapy significantly reduces distant metastases, cancer recurrence, 
and cancer-specific mortality in breast cancer patients suggesting a novel role for 
beta-blocker therapy. A larger epidemiological study leading to randomised clinical 
trials is needed for breast and other cancer types including colon, prostate and ovary.
INtrODUctION
Although an estimated 38,000 [1] patients are 
diagnosed with breast cancer in the US each year death 
rates are declining in part due to adjuvant therapies 
including the use of ER-antagonists and anti-HER2 
(trastuzumab) therapy [2-4]. Nonetheless, approximately 
30% of treated BC patients develop distant metastases 
[5]  and  these  significantly  account  for  90%  of  breast 
cancer deaths [6]. Consequently, therapeutic strategies are 
needed that target metastasis [7, 8].
Metastasis formation involves migration of 
malignant cells from the primary tumour via lymphatic 
or blood vessel routes with the process being tightly 
regulated by exogenous cell signalling molecules, 
including ligands to G protein-coupled receptors (GPCRs) 
such  as  neurotransmitters  and  chemokines  [9,  10].  In 
previous in vitro cell migration studies we have shown 
that the stress catecholamine hormone norepinephrine is 
a potent inducer of migratory activity in carcinoma cell 
lines of colon [11], prostate [12], ovarian cancer cells 
[13] and breast [14] tissue origin, and this finding has 
been confirmed in a mouse model [15]. Moreover, we 
have shown that cell migration is mediated by adrenergic Oncotarget 2010; 1:  628 - 638 629 www.impactjournals.com/oncotarget
receptors (AR) and that the process is inhibited by 
the beta-blocker adrenergic receptor antagonist drug 
propranolol which is non-selective for β1AR and β2AR 
[11, 12, 15]. Additional support for the therapeutic benefit 
of beta-blockers is provided by recent studies showing 
propranolol can reduce proliferation in human pancreatic 
cell lines [16, 17]. 
Beta-blocker drugs along with ACE-inhibitors, 
calcium channel antagonists, imidazoline receptor 
antagonists, and diuretics are clinically well characterized 
for the therapeutic treatment of hypertension and are 
proven in reducing life-threatening cerebrovascular events 
[18, 19]. Epidemiologic studies confirm that beta-blocker 
treatment per se has no effect in causing or promoting 
cancer growth giving reassurance for their continued 
clinical use [20, 21].
In the present study we hypothesised that patients 
started on and maintained with antihypertensive beta-
blocker therapy prior to their breast cancer diagnosis would 
show reduced distant metastasis formation compared to 
non-hypertensive breast cancer patients or those treated 
with other antihypertensive drugs. 
rEsULts
clinical correlations in Patients treated with beta-
blocker Drugs compared to other Hypertensive 
and Non-hypertensive breast cancer Patients
Data was obtained for 466 breast cancer patients used 
in this study and their characteristics are shown in Tables 
1a-d. A  total  of  92  (19.7%)  patients  had  hypertension 
diagnosed prior to breast cancer diagnosis and were 
therapeutically treated using a range of antihypertensives 
including beta-blockers, ACE inhibitors, Ca2+ antagonists, 
imidazoline receptor antagonists or diuretics (Table 2). In 
particular, 43/92 (46.7%) of this hypertensive subgroup 
(median age 57 years, range 39-69) received beta-blocker 
drugs while the remaining 49/92 (53.3%) patients received 
other antihypertensive drugs. The latter group significantly 
differed in showing increased median age of 62 years 
(range 47-70) compared to the non-hypertensive patient 
subgroup whose median age was 54.5 years (range 28-71). 
In addition, the non-beta-blocker treated antihypertensive 
subgroup contained an increased proportion of post-
menopausal patients (Table 1c) Otherwise, no significant 
difference was seen in tumour stage, tumour size, grade, 
type,  vascular  invasion,  Nottingham  Prognostic  Index 
(NPI) or AT between the three patient subgroups. 
Patients receiving beta-blockers showed a significant 
reduction in formation of distant metastasis (χ2=4.986, 
p=0.026)  and  tumour  recurrence  (χ2=13.091,  p=0.001) 
compared to non-hypertensive BC control patients (Table 
3). 
Hypertensive breast cancer Patients treated 
with beta-blockers compared with Other 
Antihypertensive Drugs 
Beta-blocker treated breast cancer patients differed 
significantly to patients receiving other antihypertensives 
(χ2=4.852,  p=0.028)  in  showing  reduced  development 
Figure 1a: Hypertensive BC patients therapeutically treated with beta-blockers showed significantly (p=0.022) longer 
times before acquiring metastases compared to non-treated patients.
Figure 1b. Hypertensive BC patients receiving beta-blocker therapy showed significantly (p=0.011) improved 10 year survival rates 
compared to non-treated patients.Oncotarget 2010; 1:  628 - 638 630 www.impactjournals.com/oncotarget
of distant metastasis (5/43 (11.6%)) compared to their 
counterparts  (15/49  (30.6%))  (Table  3).  In  addition, 
the  beta-blocker  treated  subgroup  showed  significantly 
reduced  tumour  recurrence  (χ2=7.264,  p=0.026;  Table 
1b). 
PAtIENt OUtcOmE
Univariate analysis:
Kaplan-Meier modelling with log rank testing 
showed beta-blocker treated patients had longer distant 
Table 1a: Characteristics for breast cancer patients therapeutically treated with beta-blockers (BB) compared to control 
breast cancer (BC) patients, excluding patients treated with other types of antihypertensive drugs.
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Tables 
Table 1a. Characteristics for breast cancer patients therapeutically treated with beta-
blockers (BB) compared to control breast cancer (BC) patients, excluding patients 
treated with other types of antihypertensive drugs.
Variable Number (%)
control bc 
patients
Number (%)
bb-treated 
patients
χ2 p-value
Patients’ Age
<40 22 (5.9) 1 (2.3)
4.079 0.253 40-50 117 (31.3) 9 (20.9)
51-60 126 (33.7) 20 (46.5)
>60 109 (29.1) 13 (30.2)
Primary tumour size
≤1.5 cm 134 (35.9) 14 (33.3)
0.111 0.740 >1.5 cm 239 (64.1) 28 (66.7)
tumour stage
1 250 (67.0) 31 (73.8)
1.176 0.555 2 89 (23.9) 9 (21.4)
3 34 (9.1) 2 (4.8)
Grade
1 75 (20.2) 7 (16.7)
2.205 0.332 2 129 (34.7) 11 (26.2)
3 168 (45.2) 24 (57.1)
NPI
Poor 43 (11.6) 6 (14.3)
0.270 0.874 Moderate 212 (57.1) 23 (54.8)
Good 116 (31.3) 13 (31.0)
Development of recurrence
No  220 (59.3) 32 (74.4) 13.091 0.001 Positive  151 (40.7) 10 (23.3)
Vascular invasion
Negative 227 (61.5) 27 (62.8)
1.788 0.409 Probable 40 (10.8) 2 (4.7)
Definite 102 (27.6) 14 (32.6)
tumour type
Ductal/NST 200 (54.6) 27 (62.8)
7.433 0.283
Lobular 42 (11.5) 4 (9.3)
Tubular and Tubular       
mixed 78 (21.3) 8 (18.6)
Medullary 11 (3.0) 1 (2.3)
Other special types* 10 (2.7) 2 (4.7)
Mixed** 24 (6.6) 0 (0)
menopausal status
Premenopausal 149 (39.8) 9 (20.9)
5.860 0.015 Postmenopausal 225 (60.2) 34 (79.1)Oncotarget 2010; 1:  628 - 638 www.impactjournals.com/oncotarget 631
Table 1b: Characteristics for breast cancer patients therapeutically treated with beta-blockers (BB) compared to breast 
cancer (BC) patients treated with other antihypertensive drugs. 
Table 1b. Characteristics for breast cancer patients therapeutically treated with beta-
blockers (BB) compared to breast cancer (BC) patients treated with other 
antihypertensive drugs.
Variable Number (%)
bc treated with 
other 
antihypertensives
Number (%)
bb-treated
χ2 p-value
Patients’ Age
<40 0 (0) 1 (2.3)
6.507 0.089 40-50 10 (20.4) 9 (20.9)
51-60 13 (26.5) 20 (46.5)
>60 26 (53.1) 13 (30.2)
Primary tumour size
≤1.5 cm 19 (39.6) 14 (33.3) 0.377 0.539 >1.5 cm 29 (60.4) 28 (66.7)
tumour stage
1 31 (66.0) 31 (73.8)
0.817 0.665 2 12 (25.5) 9 (21.4)
3 4 (8.5) 2 (4.8)
Grade
1 12 (25.0) 7 (16.7)
2.215 0.330 2 16 (33.3) 11 (26.2)
3 20 (41.7) 24 (57.1)
NPI
Poor 5 (10.2) 6 (14.3)
1.065 0.587 Moderate 24 (49.0) 23 (54.8)
Good 20 (40.8) 13 (31.0)
Development of recurrence
No  25 (51.0) 32 (74.4) 7.264 0.026 Positive  24 (49.0) 10 (23.3)
Vascular invasion
Negative 30 (61.2) 27 (62.8)
1.811 0.404 Probable 6 (12.2) 2 (4.7)
Definite 13 (26.5) 14 (32.6)
tumour type
Ductal/NST 26 (53.1) 27 (62.8)
8.269 0.309
Lobular 3 (6.1) 4 (9.3)
Tubular and Tubular       
mixed 15 (30.6) 8 (18.6)
Medullary 2 (4.1) 1 (2.3)
Other special types* 0 (0) 2 (4.7)
Mixed** 2 (4.1) 0 (0)
menopausal status
Premenopausal 12 (24.5) 9 (20.9) 0.165 0.685 Postmenopausal 37 (75.5) 34 (79.1)Oncotarget 2010; 1:  628 - 638 www.impactjournals.com/oncotarget 632
Table 1c: Characteristics for breast cancer patients therapeutically treated with antihypertensive drugs (excluding beta 
blockers) compared to control breast cancer (BC) patients. 
Table 1c. Characteristics for breast cancer patients therapeutically treated with 
antihypertensive drugs (excluding beta blockers) compared to control breast cancer 
(BC) patients.
Variable Number (%)
control bc 
patients 
Number (%)
bc treated with 
other 
antihypertensives
χ2 p-value
Patients’ Age
<40 22 (5.9) 0 (0)
12.708 0.005
40-50 115 (30.7) 10 (20.4)
51-60 127 (34.0) 131 (26.5)
>60 110 (29.4) 26 (53.1)
Primary tumour size
≤1.5 cm 134 (35.9) 19 (39.6) 0.246 0.620 >1.5 cm 239 (64.1) 29 (60.4)
tumour stage
1 249 (66.9) 31 (66.0)
0.069 0.966 2 89 (23.9) 12 (25.5)
3 34 (9.1) 4 (8.5)
Grade
1 74 (19.9) 12 (25.0)
0.709 0.702 2 128 (34.4) 16 (33.3)
3 170 (45.7) 20 (41.7)
NPI
Poor 43 (11.6) 5 (10.2)
1.917 0.384 Moderate 213 (57.4) 24 (49.0)
Good 115 (31.0) 20 (40.8)
Development of recurrence
No  218 (58.8) 25 (51.0) 1.063 0.302 Positive  153 (41.2) 24 (49.0)
Vascular invasion
Negative 228 (61.8) 30 (61.2)
0.057 0.972 Probable 41 (11.1) 6 (12.2)
Definite 100 (27.1) 13 (26.5)
tumour type
Ductal/NST 201 (54.9) 26 (53.1)
12.228 0.093
Lobular 42 (11.5) 3 (6.1)
Tubular and Tubular       
mixed 78 (21.3) 15 (30.6)
Medullary 11 (3.0) 2 (4.1)
Other special types* 9 (2.5) 0 (0)
Mixed** 24 (6.6) 2 (4.1)
menopausal status
Premenopausal 147 (39.3) 12 (24.5) 4.053 0.044 Postmenopausal 229 (60.7) 37 (75.5)Oncotarget 2010; 1:  628 - 638 www.impactjournals.com/oncotarget 633
Table 1d: Characteristics for breast cancer patients therapeutically treated with beta-blockers (BB) compared to all other 
patients including those receiving other antihypertensive drug treatment. 
Table 1d. Characteristics for breast cancer patients therapeutically treated with beta-
blockers (BB) compared to all other patients including those receiving other 
antihypertensive drug treatment. 
Variable Number (%)
All other 
patients 
Number (%)
bb-treated
χ2 p-value
Patients’ Age
<40 22 (5.2) 1 (2.3)
3.926 0.270 40-50 127 (30.1) 9 (20.9)
51-60 139 (32.9) 20 (46.5)
>60 135 (31.9) 13 (30.2)
Primary tumour size
≤1.5 cm 153 (36.3) 14 (33.3) 0.150 0.699 >1.5 cm 268 (63.7) 28 (66.7)
tumour stage
1 281 (66.9) 31 (73.8)
1.190 0.552 2 101 (24.0) 9 (21.4)
3 38 (9.0) 2 (4.8)
Grade
1 87 (20.7) 7 (16.7)
2.368 0.306 2 145 (34.5) 11 (26.2)
3 188 (44.8) 24 (57.1)
NPI
Poor 48 (11.4) 6 (14.3)
0.305 0.859 Moderate 236 (56.2) 23 (54.8)
Good 136 (32.4) 13 (31.0)
Development of recurrence
No  244 (58.2) 33 (78.6) 6.854 0.010 Positive  175 (41.8) 9 (21.4)
Vascular invasion
Negative 257 (61.5) 27 (62.8)
1.877 0.391 Probable 46 (11.0) 2 (4.7)
Definite 115 (27.5) 14 (32.6)
tumour type
Ductal/NST 233 (55.5) 28 (65.1)
3.534 0.832
Lobular 46 (10.9) 4 (9.3)
Tubular and Tubular       
mixed 92 (21.9) 7 (16.3)
Medullary 13 (3.1) 1 (2.3)
Other special types* 10 (2.4) 2 (4.6)
Mixed** 26 (6.2) 1 (2.3)
menopausal status
Premenopausal 160 (37.9) 11 (25.6) 2.553 0.110 Postmenopausal 262 (62.1) 32 (74.4)
*Includes Mucoid, invasive cribriform and invasive papillary carcinoma. ** Includes
ductal/NST mixed with lobular or special types.Oncotarget 2010; 1:  628 - 638 634 www.impactjournals.com/oncotarget
metastasis-free interval (Log rank (LR)=5.208, p=0.022) 
(Fig  1a)  and  longer  breast  cancer  specific  survival 
(LR=6.479, p=0.011) (Fig 1b), and longer disease free 
interval  (LR=6.658,  p=0.011)  when  compared  to  non-
treated breast cancer patients. 
multivariate analysis: 
A multivariate Cox hazard model was used to 
determine the hazard ratio (HR) for predicting breast 
cancer  specific  survival  and  distant  metastasis  risk  in 
patients receiving beta-blocker treatment compared to 
other significant breast cancer variables including tumour 
size, stage and grade. Patients receiving beta-blocker 
treatment had a 71% reduced risk of cancer-associated 
mortality  (HR=0.291,  CI=  0.119-0.715,  p=0.007).  In 
addition, beta-blocker treated patients showed a 57% risk 
reduction  in  developing  distant  metastasis  (HR=0.430, 
CI=  0.200-0.926,  p=0.031; Table  4)  compared  to  non-
treated breast cancer patients. 
DIscUssION
Evidence of the biological mechanism between 
stress hormones and tumour cell migration 
Tumour metastasis is a complex process and 
is associated with generally poor clinical outcome. 
Therapeutic strategies are needed that can prevent its 
occurrence, thereby prolonging patient life. The present 
study was performed to validate the putative role of beta-
blocker adrenergic receptor antagonists in retarding the 
progress of breast cancer disease by reducing metastasis 
formation. We performed an epidemiological study of 
breast cancer patients with long term clinical follow 
up (>10 years) and showed that patients receiving 
antihypertensive beta-blocker drugs significantly benefit 
by a 57% reduction in distant metastasis formation and a 
71% reduced risk of dying from breast cancer compared 
to control patients.
It is increasingly being recognised that stress can 
promote cancer progression through an indirect effect 
on the immune system [22]. Moreover, a biological 
mechanism of action has been proposed for the involvement 
of  catecholamine  stress  hormones.  It  has  been  shown 
that norepinephrine can directly stimulate tumour cell 
migration and this effect is mediated by the beta-adrenergic 
receptor, β2AR. High levels of β2AR have been reported 
in human cell lines [11, 23, 24] and tumour samples [25] 
and importantly, we have shown that cell migration in a 
number of cancer models is inhibited by the beta-blocker 
adrenergic receptor antagonist, propranolol [11, 12, 14].   
 
Proof-of principle epidemiological pilot study 
shows beta-blocker drugs reduce metastasis 
and tumour recurrence in patients with breast 
cancer,  leading  to  an  improvement  in  survival   
The aim of the current study was to translate these 
findings into a clinical setting by testing the hypothesis 
that breast cancer patients receiving beta-blockers for pre-
existing hypertension would show a significant reduction 
in tumour metastasis with a consequent reduction in 
mortality. 
In  line  with  expectations,  antihypertensive  drug 
treatment was more frequently prescribed in older post-
menopausal patients with no significant difference seen 
between the beta-blocker and other antihypertensive 
treatment subgroups. The beta-blocker treated subgroup 
was shown to have significantly (57%) reduced risk of 
developing distant metastasis and tumour recurrence 
compared to patients receiving either no, or other types 
of, antihypertensive drugs. As a consequence of this, beta-
blocker  treated  patients  showed  a  significant  increase 
in breast cancer specific survival and increased disease 
free interval. To the best of our knowledge, this is the 
first report highlighting the in vivo therapeutic benefits 
of beta-blockers in breast cancer patients, supporting the 
biological mechanism of norepinephrine-induced cell 
migration mediated by adrenergic receptor activation as 
shown in cell lines and animal models. These findings 
support recent epidemiological cancer studies that have 
Table 2: Beta-blocker and other therapeutic drugs were 
used  to  treat  breast  cancer  patients  for  pre-existing 
hypertension.
Table 2. Beta-blocker and other therapeutic drugs were used to treat breast cancer 
patients for pre-existing hypertension.
Drug Patient Numbers
beta-blockers
Atenolol 25
Propranolol 7
Bisoprolol 7
Timolol 4
Subtotal  43
Other drug treatments
Captopril (ACE-Inhibitor) 6
Ramipril (ACE-Inhibitor) 4
Enalapril (ACE-Inhibitor) 3
Lisinopril (ACE-Inhibitor) 3
Nifedipine (Ca2+ antagonist) 5
Amlodipine (Ca2+ antagonist) 5
Nicardipine (Ca2+ antagonist) 1
Moxonidine (Imidazoline 
receptor antagonist)
1
Bendrofluazide (Diuretic) 21
Subtotal 49
total 92Oncotarget 2010; 1:  628 - 638 635 www.impactjournals.com/oncotarget
shown adrenoceptor antagonists have the potential for 
providing a novel clinically effective therapeutic strategy 
in treating several different cancer types. Beta-blockers 
have been shown to reduce the incidence of endocrine-
regulated prostate cancer [26], but this beneficial effect 
is not just limited to inhibition of beta receptors because 
patients receiving alpha antagonists also show a reduced 
incidence of prostate [27] and bladder [28] cancer. 
Moreover, a generalised reduction in all cancer types has 
been reported in beta-blocker treated patients [29].  
study limitations
Several limitations apply to our epidemiological 
study including patient population size and factors that 
were not controlled for in using an existing patient dataset. 
In mitigation, the beta-blocker and other hypertensive-
treated cohort were of approximately the same size and 
together accounted for approximately 20% of the total 
patient  cohort.  In  addition,  all  patient  subgroups  were 
evenly matched for adjuvant therapy and age making it 
unlikely that this was the reason for the significant benefits 
seen in the beta-blocker group. A further possible limitation 
is that it is unknown (and impossible to establish) how 
long patients had breast cancer prior to a formal diagnosis, 
and so the duration required for beta-blockers to prevent 
development of metastases can not be calculated from this 
type of study. Some of these limitations can be addressed 
by performing a much larger epidemiological study, 
leading onto a randomised controlled clinical trial. The 
latter would determine a) If beta-blocker drugs can be 
used as a prophylactic for metastatic formation in breast 
cancer, b) The optimal adjuvant therapy dosage in breast 
cancer, c) Whether beta-blocker treatment is effective in 
clinically treating patients with other types of cancer, e.g. 
prostate, pancreatic and colonic cancer, suggested by our 
cell line models.
Future studies
The current study suggests that adrenoceptor 
antagonists have the potential for retarding breast cancer 
progression and improving clinical outcome. Additional 
studies are needed to assess the protein expression of 
adrenoceptors in breast and other cancer types to test if 
they can be used as prognostic and predictive biomarkers 
in determining clinical outcome and likely response to 
antagonist treatment. 
mAtErIALs AND mEtHODs
Patient selection 
Therapeutic drug and medical history was obtained 
for  466  patients  with  stage  I  and  II  primary  operable 
breast carcinoma, aged 71 years or less, who presented 
Table 3: Two hypertensive breast cancer (BC) patient groups comprising those treated with beta-blockers and non-beta 
blocker antihypertensive drugs were compared with a non-hypertensive non-treated bc group for formation of distant 
metastases.
Table 3. Two hypertensive breast cancer (BC) patient groups comprising those treated 
with beta-blockers and non-beta blocker antihypertensive drugs were compared with a 
non-hypertensive non-treated BC group for formation of distant metastases.
metastasis
formation
treatment in breast 
cancer groups χ
2 P-value
Non-
hypertensive 
patients 
(%)
beta-blocker 
treated 
hypertensives
(%)
Negative 271 (72.7) 38 (88.4)
4.986 0.026
Positive 102 (27.3) 5 (11.6)
Other treated 
anti-
hypertensive 
patients (%)
beta-blocker 
treated 
patients
(%)
Negative 34 (69.4) 38 (88.4) 4.852 0.028
Positive 15 (30.6) 5 (11.6)
Non 
hypertensive 
bc patients 
(%)
Other anti-
hypertensive 
patients
Negative 271 (72.7) 34 (69.4)
0.231 0.631 Positive 102 (27.3) 15 (30.6)Oncotarget 2010; 1:  628 - 638 636 www.impactjournals.com/oncotarget
consecutively to the Nottingham City Hospital between 
1987  and  1994  as  previously  reported  [30].  Patients 
were placed into one of three subgroups according to 
whether they received (1) beta-blocker treatment for 
hypertension, (2) other antihypertensive drug treatment, 
or were (3) normotensive. To qualify for subgroup (1) or 
(2) membership, patients needed to have been receiving 
antihypertensive therapy for at least 1 year prior to 
breast cancer diagnosis. This criterion was applied to 
minimise  differences  due  to  length  of  drug  treatment; 
patients that received hypertensive drugs for less than 1 
year were excluded because the primary objective tested 
was that beta-blockers may have a role in preventing 
metastasis formation in early stage breast cancer rather 
than eradicating or neutralising established primary and 
secondary cancers.
Patient’s clinical and pathologic data was available 
including age, histologic tumour type, primary tumour 
size, lymph node status and histologic grade, Nottingham 
prognostic index (NPI), vascular invasion (VI), and radio/
chemotherapy. Patients were considered for adjuvant 
therapy (AT) in a standardised scheduled on the basis 
of prognostic and predictive factor status including 
Nottingham  Prognostic  Index  (NPI)  [31],  oestrogen 
receptor-α (ERα) status, and menopausal status. Patients 
with a good prognostic index (NPI ≤3.4) did not receive 
AT. Hormonal therapy (HT) was prescribed to patients 
with ERα+ tumours and NPI scores of >3.4 (moderate 
and poor prognostic groups). Pre-menopausal patients 
within the moderate and poor prognostic groups were 
candidates for CMF (Cyclophosphamide, Methotrexate, 
and  5-Flourouracil)  chemotherapy;  patients  with  ERα+ 
tumour were also offered HT. Conversely, postmenopausal 
patients with moderate or poor NPI and ERα+ were offered 
HT, while ERα- patients received CMF. Data has been 
accrued on a prospective basis for breast cancer specific 
survival (BCSS), disease free interval (DFI), formation 
of distant metastases (DM) and local tumour recurrence. 
BCSS was defined as the time (in months) from the date 
of the primary surgical treatment to the time of death from 
breast cancer. DFI was defined as the interval (in months) 
from the date of the primary surgical treatment to the first 
locoregional or distant metastasis. Mean follow-up time 
was 124 months for the study cohort.
Univariate and multivariate statistics 
The clinical outcome in three patient cohorts (beta-
blocker drug treated, other antihypertensive drug treated, 
and non-hypertensive breast cancer groups) was tested 
using Kaplan-Meier plots with log rank test to assess 
significance  including  breast  cancer  specific  survival, 
disease free interval, and distant metastasis formation. 
Other associations including tumour recurrence was tested 
using Chi square or Fishers exact test. Multivariate Cox 
regression analysis was used to evaluate the hazard ratio 
and any independent prognostic effect of the variables 
using 95% confidence interval (Version 15, SPSS Inc, IL, 
USA). A p-value of <0.05 was considered significant.
AcKNOWLEDGEmENts 
We thank the ministry of higher education (Egypt) for 
funding HO Habashy. Supported in part by Fritz-Bender-
Foundation, Munich. In addition, the kind assistance of 
Mrs Pat Ward and the Medical Records department is 
acknowledged.
cONFLIct OF INtErEst stAtEmENt
The authors do not have any conflicts of interest to 
declare. 
Table 4: The effect of beta-blocker treatment on breast cancer specific survival (BCSS) and distant metastasis (DM) 
formation was compared with tumour size, grade and stage to determine the relative risk (Hazard Ratios (HR)) in BC 
patients.
Table 4. The effect of beta-blocker treatment on breast cancer specific survival 
(BCSS) and distant metastasis (DM) formation was compared with tumour size, grade 
and stage to determine the relative risk (Hazard Ratios (HR)) in BC patients.
Parameter Hr p-value 95% Confidence Interval
Lower Upper
bcss
1.985 0.004 1.248 3.159
1.904 <0.001 1.435 2.526
1.565 <0.001 1.218 2.011
Tumour size
Tumour grade
Tumour stage
beta-blocker treatment 0.291 0.007 0.119 0.715
Dm
1.916 0.005 1.221 3.005
1.519 0.002 1.171 1.971
1.624 <0.001 1.270 2.076
Tumour size
Tumour grade
Tumour stage
beta-blocker treatment 0.430 0.031 0.200 0.926Oncotarget 2010; 1:  628 - 638 637 www.impactjournals.com/oncotarget
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